



LUND UNIVERSITY

Multiple Sclerosis: Studies of the Interferon system and search for infectious agents

Bergkvist, My

2005

[Link to publication](#)

Citation for published version (APA):

Bergkvist, M. (2005). *Multiple Sclerosis: Studies of the Interferon system and search for infectious agents*. [Doctoral Thesis (compilation), Neurology, Lund]. Department of Clinical Neuroscience, Lund University.

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00



Short Communication

No genetic linkage between multiple sclerosis and the interferon α/β locus

My Bergkvist ^{a,*}, Tommy Martinsson ^b, Pierre Åman ^c, Magnhild Sandberg-Wollheim ^a

^a Department of Neurology, University Hospital, S-22185 Lund, Sweden

^b Department of Clinical Genetics, East Hospital, S-41685 Gothenburg, Sweden

^c Department of Clinical Genetics, University Hospital, S-22185 Lund, Sweden

Received 12 July 1995; revised 22 December 1995; accepted 25 January 1996

Abstract

Multiple sclerosis (MS) is probably caused by an interaction of genetic and environmental factors. The genetic component is reflected by a ten-fold higher concordance rate in monozygotic (27%) compared to dizygotic (3%) twin pairs. Treatment with interferon was recently reported to have a favorable effect in patients with relapsing-remitting MS. In the present familial study, we have investigated the possibility of a genetic association between the highly polymorphic Interferon $\alpha\beta$ locus and the development of MS. Based on our data, we conclude that there is no linkage between the Interferon $\alpha\beta$ locus and MS.

Keywords: Multiple sclerosis; Interferon; Genetic linkage; DNA

1. Introduction

MS is a neurodegenerative disease with an incidence of 3–5 per 100 000 in the nordic countries. The etiology is not known but the results from many studies of MS suggest that the disease is caused by an interaction of genetic and environmental factors (Ebers and Sadovnick, 1994).

The genetic component is reflected by the higher concordance rate in monozygotic (27%) compared to dizygotic (3%) twin pairs (Sadovnick et al., 1993; Mumford et al., 1994) and a higher prevalence of the disease in first degree relatives of patients (Sadovnick and Baird, 1988).

Results from family studies suggest that susceptibility-associated genes are located within the HLA complex on the short arm of chromosome 6. The myelin basic protein (MBP) gene and the tumor necrosis factor genes (TNF) are other candidate genes for MS susceptibility, although results from family studies of the former are contradictory (Tienari et al., 1992; Graham et al., 1993; Rose et al., 1993).

CSF T-cell clones from patients with MS have been

found to produce more interferon gamma (IFN γ) and TNF α than control cell clones from healthy donors (Benvenuto et al., 1992). There are also results indicating that TNF α levels correlate with disease progression and severity (Sharief and Thompson, 1992).

Treatment with interferon β (IFN β) was recently reported to have a favorable effect in MS patients with relapsing-remitting disease. A significant reduction in exacerbation rates, severity of exacerbations, and accumulation of MRI abnormalities was noted (The IFN β Multiple Sclerosis Study Group, 1993; Paty et al., 1993). The mechanism of action of IFN β that is responsible for these positive results is still unknown. Results from earlier studies show that IFN β has the ability to inhibit or decrease IFN γ (Panitch et al., 1987; Noronha et al., 1991, 1993) and to augment defective suppressor cell function in MS patients (Noronha et al., 1990).

IFN γ enhances antigen presentation by increasing class II MHC antigens and thus IFN β counteracts these effects (Panitch et al., 1989). This may indicate that the IFN system is somehow involved in the development of MS.

The IFN α and IFN β genes share extensive homology and are located closely linked to each other in the same or adjacent bands on the short arm of chromosome 9. The IFN γ gene is located on the long arm of chromosome 12 and shows no homology with IFN α or β (Ohlsson et al.,

* Corresponding author. Tel. +46 (46) 171 421; Fax +46 (46) 158 919.

1985). A high degree of polymorphism has been identified in the human IFN α and β gene regions (Ohlsson et al., 1985).

In the present familial study we investigated the possibility of a genetic association between the IFN $\alpha\beta$ locus and the development of MS.

2. Material and methods

2.1. Patients and controls

126 Swedish individuals belonging to 24 unrelated families with at least two members with clinically definite MS by standard criteria (Poser et al., 1983) were studied. The patients consisted of 18 men and 33 women. The mean age of the patients was 48.3 years (range 28–71). The mean age at onset of the disease was 28.4 years (range 16–71). The onset age for four of the patients was not known. Clinical subtypes were not defined. Unaffected members of the families had an average age of 60.3 years (range 27–87); 41 were men and 34 were women. The controls were healthy blood donors, 63 men and 78 women, of the same ethnic origin as the patients. None of the controls were related to the patient families.

2.2. Method

DNA was isolated from peripheral blood and a microsatellite polymorphism in the IFN α locus was analyzed by PCR with primers TGCGCGTTAAGTTAATTGGTT and GTAAGGTGGAAACCCCACT (19). The samples were predenatured at 98°C for 2 min followed by 30 cycles of 94°C for 30 s, 53°C for 30 s, and 72°C for 40 s.

2.3. Statistics

Two-point linkage analysis was performed with the MLINK program from the LINKAGE 5.1 package (Lathrop et al., 1984). The model applied for analyses was autosomal dominant inheritance, and several different levels of penetrance were tested. A gene frequency of the

Table 1
IFN α/β allele frequencies in MS patients and controls

Allele	No. of chromosomes	
	MS patients ^a	Controls
1: 152 bp	1 (0.02)	5 (0.02)
2: 150 bp	11 (0.23)	54 (0.19)
3: 148 bp	23 (0.48)	147 (0.52)
4: 146 bp	5 (0.10)	34 (0.12)
5: 142 bp	8 (0.17)	42 (0.15)
6: 138 bp	0 (0.00)	0 (0.00)
Total	48	282

^a One randomly chosen patient from each family.

Table 2

Two-point lod score values for linkage between MS in the 24 families and an IFN β polymorphism

Penetrance	Recombination fraction (θ)						
	0	0.01	0.05	0.1	0.2	0.3	0.4
0.2	-5.90	-4.96	-3.11	-1.95	-0.79	-0.26	-0.03
0.3	-6.33	-5.30	-3.36	-2.16	-0.91	-0.31	-0.04
0.5	-7.38	-6.05	-3.91	-2.59	-1.15	-0.42	-0.08

disease allele of 0.01 was used for the calculations. For affected sib-pair analysis, the ESPA program (version 2.2) by Sandkuyl (1989) was applied. Also partially informative sib-pairs were included in the analysis. The estimations for allele frequency used were those of the healthy control population presented in Table 1.

3. Results

We investigated 267 individuals, six of whom had a previously unknown allele comprising 152 base pairs. Five alleles with 138, 142, 146, 148, and 150 base pairs, respectively, have previously been reported in the polymorphic CA repeat of the IFN β (Kwiatkowski and Diaz, 1992). Our MS patients and healthy controls showed a similar distribution of the alleles (Table 1). A homogeneity test of the two materials using one randomly chosen affected individual from each MS family gave a χ^2 of 1.28, $P = 0.86$.

Two-point linkage analysis using the MLINK program was performed on data from the 24 families. Several levels of penetrance for MS were tested. The results of these analyses are presented in Table 2.

At no θ -value did the lod score (Z) exceed 0, i.e. no evidence of linkage was detected between MS and IFN β in the family material. For instance, at penetrance level 0.3 linkage was excluded (i.e. Z below -2.0) until θ reaches 0.11.

We also analyzed the family material with an affected sib-pair method using the ESPA program (Extended Sib-Pair Analysis; Sandkuyl, 1989). Data were available in 14 families with affected sib-pairs. The data for the ESPA analysis gave a χ^2 of 1.2 and $P = 0.84$. Therefore, evidence for an increased sharing of alleles, identical by descent (IBD) was not detected in the material.

4. Discussion

We have analyzed a group of Swedish MS families for possible genetic linkage between the disease and the IFN α/β locus. None of the 6 alleles were over-represented in the patient group and we conclude from the data analysis that there is no linkage between the IFN α/β and MS. These results indicate that the IFN α - and the tightly

linked IFN β -locus are not involved in the development of the disease and also rule out the possibility of a defective IFN β -production in MS patients. The positive effect of IFN β treatment in MS is, therefore, not achieved by a reconstitution of IFN β production.

Acknowledgements

This work was supported by grants from the Swedish Medical Research Council (Project No. B95-19X-06265-14B), the Medical Faculty of the University of Lund, the Thorsten and Elsa Segerfalk Foundation, and the Thelma Zoéga Foundation. M.B. was a recipient of a scholarship from Serono Nordic AB, Stockholm, Sweden.

References

- Benvenuto, R., Paroli, M., Butinelli, C., Franco, A., Barnaba, V., Fieschi, C. and Balsano, F. (1992) Tumor necrosis factor-alpha and interferon-gamma synthesis by cerebrospinal fluid-derived T cell clones in multiple sclerosis. *Ann. N.Y. Acad. Sci.* 650, 341–346.
- Ebers, G. and Sadovnick, A.D. (1994) The role of genetic factors in MS susceptibility. *J. Neuroimmunol.* 59, 1–17.
- Graham, C.A., Kirk, C.W., Nevin, N.C., Droogan, A.G., Hawkins, S.A., McMillan, S.A. and McNeill, T.A. (1993) Lack of association between myelin basic protein gene microsatellite and multiple sclerosis. *Lancet* 341, 1596.
- Kwiatkowski, D. and Diaz, M.O. (1992) Dinucleotide repeat polymorphism at the IFNA locus (9p22). *Human Mol. Genet.* 1, 658.
- Lathrop, G.M., Lalouci, J.M. and Julier, C. (1984) Strategies for multilocus linkage analysis in humans. *Proc. Natl. Acad. Sci. USA* 81, 3443–3446.
- Mumford, C.J., Wood, N.W., Kellar-Wood, H., Thorpe, T.W., Miller, D.H. and Compston, D.A.S. (1994) The British Isles survey of multiple sclerosis in twins. *Neurology* 44, 11–15.
- Noronha, A., Toscas, A. and Jensen, M.A. (1991) IFN-beta down-regulates IFN-gamma production by activated T cells in Multiple Sclerosis. *Neurology* 41 (suppl. 1), 219.
- Noronha, A., Toscas, A. and Jensen, M.A. (1993) Interferon beta decreases T cell activation and interferon gamma production in Multiple Sclerosis. *J. Neuroimmunol.* 46, 145–154.
- Noronha, A., Toscas, A. and Jensen, M.A. (1990) Interferon beta augments suppressor cell function in Multiple Sclerosis. *Ann. Neurol.* 27, 207.
- Ohlsson, M., Feder, J., Cavalli-Storza, L.L. and Von Gabain, A. (1985) Close linkage of alpha and beta interferones and infrequent duplication of beta interferon in humans. *Proc. Natl. Acad. Sci. USA* 82, 4473–4476.
- Panitch, H.S., Folus, J.S. and Johnson, K.P. (1987) Recombinant Beta Interferon Inhibits Gamma Interferon Production in Multiple Sclerosis. *Ann. Neurol.* 22, 139.
- Panitch, H.S., Folus, J.S. and Johnson, K.P. (1989) Beta interferon prevents HLA class II antigen induction by gamma interferon in MS (abstract). *Neurology* 39 (suppl. 1), 171.
- Paty, D.W. and Li, D.K.B., The UBC MS/MRI Study Group and The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized double-blind, placebo-controlled trial. *Neurology* 43, 662–667.
- Poser, C.M., Paty, D.W., Scheinberg, L., McDonald, W.I., Davis, F.A., Ebers, G.C., Johnson, K.P., Sibley, W.A., Silberberg, D.H. and Tourtelotte, W.W. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann. Neurology* 13, 227–231.
- Rose, J., Gerken, S., Lynch, S., Pisani, P., Varvil, T., Otterud, B. and Leppert, M. (1993) Genetic susceptibility in familial multiple sclerosis not linked to the myelin basic protein gene. *Lancet* 341, 1179–1181.
- Sandkuyil, L.A. (1989) Analysis of affected sib-pairs using information from extended families. In: R.C. Elston, M.A. Spence, S.E. Hodge, et al. (Eds.), *Multipoint Mapping and Linkage Based Upon Affected Pedigree Members: Genetic Analysis Workshop 6*, Alan R. Liss, New York, NY.
- Sadovnick, A.D., Armstrong, H., Rice, G.P.A., Bulman, D., Hashimoto, L., Paty, D.W., Hashimoto, S.A., Warren, S., Hader, W., Murray, T.J., Seland, T.P., Metz, L., Bell, R., Duquette, P., Gray, T., Nelson, R., Weinschenker, B., Brunet, D. and Ebers, G.C. (1993) A population-based study of multiple sclerosis in twins: update. *Ann. Neurol.* 33, 281–285.
- Sadovnick, A.D. and Baird, P.A. (1988) The familial nature of multiple sclerosis: Age-correlated empiric recurrence risks for children and siblings of patients. *Neurology* 38, 990–991.
- Sharief, M.K. and Thompson, E.J. (1992) In vivo relationship of tumor necrosis factor alpha to blood-brain barrier damage in patients with active multiple sclerosis. *J. Neuroimmunol.* 38, 27–33.
- Tienari, P.J., Wikström, J., Sajantila, A., Palo, J. and Peltonen, L. (1992) Genetic susceptibility to multiple sclerosis linked to myelin basic protein gene. *Lancet* 340, 987–991.
- The IFN β Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology* 43, 655–661.